Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Application of 2016 MAS classification criteria to patients with MAS treated with tocilizumab

From: Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

 TocilizumabHistoric cohort
Number with sufficient data2101210818
MAS (%, n)50 (1/2)20 (2/10)25 (3/12)90 (9/10)75 (6/8)83 (15/18)
Reasons missing (n)Afebrile [1]Afebrile [4] Afebrile [1]Other markers [2] 
Ferritin [5]
  1. MAS Macrophage activation syndrome